Toinv,

Bear or one of the investigators who works with clinical trial data may have more pertinent knowledge for human trial results, but there is a general rule of thumb that the correction in science for multiple tests on a single data set is to divide your target P value by the number of tests conducted.  So, just to correct for the 5 secondary outcomes shown on the Secondary Outcomes slide, would require dividing the nominal target P value of 0.05 by five.  In other words, an unadjusted P value of 0.01 is required.  The reduced MACE in the low eGFR group achieved an unadjusted P value of 0.032.  And that is without adjusting for all the other secondary endpoints shown on the previous slide. 

So, this result is not significant.  Full stop. 

That is the problem that RVX has right now, a reasonably full dance card of shining possibilities but no one to take home (or to the FDA) after the ball.

Jupe